A PHASE 2, DOUBLE-BLIND, REPEAT-DOSE, PLACEBO-CONTROLLED CROSSOVER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CRD-4730 IN PARTICIPANTS WITH CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515564-32-00

Acronym

CRD-4730-202

Enrollment

Registered

2025-04-01

Start date

2025-11-20

Completion date

Unknown

Last updated

2025-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Catecholaminergic Polymorphic Ventricular Tachycardia

Brief summary

The number and severity of treatment-emergent adverse events (TEAEs) related to study drug treatment

Detailed description

Change in VA score during EST from baseline to Day {CCI}, from baseline to Day {CCI}, and from baseline to Day {CCI}, Plasma concentrations of CRD-4730 over time for each treatment period

Interventions

DRUGCRD-4730

DRUGCRD-4730 matching placebo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The number and severity of treatment-emergent adverse events (TEAEs) related to study drug treatment	—

Secondary

Measure	Time frame
Change in VA score during EST from baseline to Day {CCI}, from baseline to Day {CCI}, and from baseline to Day {CCI}, Plasma concentrations of CRD-4730 over time for each treatment period	—

Countries

France, Italy, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026